Cholangiocarcinoma therapy with nanoparticles that combine downregulation of MicroRNA-210 with inhibition of cancer cell invasiveness

Ying Xie, Yazhe Wang, Jing Li, Yu Hang, Lee Jaramillo, Cody J. Wehrkamp, Mary Anne Phillippi, Ashley M. Mohr, Yi Chen, Geoffrey A Talmon, Justin L Mott, David Oupicky

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

Cholangiocarcinoma (CCA) is the second most common primary liver malignancy with extremely poor therapeutic outcome due to high drug resistance, widespread metastasis and lack of effective treatment options. CCA progression and metastasis are regulated by multiple biological factors including multiple miRNAs and chemokine receptor CXCR4. The goal of this study was to test if nanotherapeutic blockade of CXCR4 by polymeric CXCR4 antagonist (PCX) combined with inhibition of hypoxia-inducible miR-210 cooperatively enhances therapeutic efficacy in CCA through reducing invasiveness, inducing cell killing, and reversing drug resistance. Methods: We first tested the activity of PCX to inhibit migration of CCA cells. We then prepared PCX/anti-miRNA nanoparticles and analyzed their miRNA delivery efficacy and anticancer activity in vitro. Finally, in vivo biodistribution assay and anticancer activity study were performed in CCA tumor-bearing mice. Results: Our results show that PCX had a broad inhibitory effect on cell migration, effectively delivered anti-miR-210, and downregulated miR-210 expression in CCA cells. Combination PCX/anti-miR-210 nanoparticles showed cytotoxic activity towards CCA cells and reduced the number of cancer stem-like cells. The nanoparticles reversed hypoxia-induced drug resistance and sensitized CCA cells to standard gemcitabine and cisplatin combination treatment. Systemic intravenous treatment with the nanoparticles in a CCA xenograft model resulted in prominent combined antitumor activity. Conclusion: Our findings support PCX-based nanoparticles as a promising delivery platform of therapeutic miRNA in combination CCA therapies.

Original languageEnglish (US)
Pages (from-to)4305-4320
Number of pages16
JournalTheranostics
Volume8
Issue number16
DOIs
StatePublished - Jan 1 2018

Fingerprint

Cholangiocarcinoma
MicroRNAs
Nanoparticles
Down-Regulation
Neoplasms
Drug Resistance
Therapeutics
gemcitabine
Cell Movement
Neoplasm Metastasis
Neoplastic Stem Cells
Chemokine Receptors
Biological Factors
Heterografts
Cisplatin
Cell Count

Keywords

  • Cholangiocarcinoma
  • Drug resistance
  • Hypoxia
  • MiRNA
  • Nanoparticles

ASJC Scopus subject areas

  • Medicine (miscellaneous)
  • Pharmacology, Toxicology and Pharmaceutics (miscellaneous)

Cite this

Cholangiocarcinoma therapy with nanoparticles that combine downregulation of MicroRNA-210 with inhibition of cancer cell invasiveness. / Xie, Ying; Wang, Yazhe; Li, Jing; Hang, Yu; Jaramillo, Lee; Wehrkamp, Cody J.; Phillippi, Mary Anne; Mohr, Ashley M.; Chen, Yi; Talmon, Geoffrey A; Mott, Justin L; Oupicky, David.

In: Theranostics, Vol. 8, No. 16, 01.01.2018, p. 4305-4320.

Research output: Contribution to journalArticle

Xie, Ying ; Wang, Yazhe ; Li, Jing ; Hang, Yu ; Jaramillo, Lee ; Wehrkamp, Cody J. ; Phillippi, Mary Anne ; Mohr, Ashley M. ; Chen, Yi ; Talmon, Geoffrey A ; Mott, Justin L ; Oupicky, David. / Cholangiocarcinoma therapy with nanoparticles that combine downregulation of MicroRNA-210 with inhibition of cancer cell invasiveness. In: Theranostics. 2018 ; Vol. 8, No. 16. pp. 4305-4320.
@article{ff153aa15c584353bce5cea3d1d0360f,
title = "Cholangiocarcinoma therapy with nanoparticles that combine downregulation of MicroRNA-210 with inhibition of cancer cell invasiveness",
abstract = "Cholangiocarcinoma (CCA) is the second most common primary liver malignancy with extremely poor therapeutic outcome due to high drug resistance, widespread metastasis and lack of effective treatment options. CCA progression and metastasis are regulated by multiple biological factors including multiple miRNAs and chemokine receptor CXCR4. The goal of this study was to test if nanotherapeutic blockade of CXCR4 by polymeric CXCR4 antagonist (PCX) combined with inhibition of hypoxia-inducible miR-210 cooperatively enhances therapeutic efficacy in CCA through reducing invasiveness, inducing cell killing, and reversing drug resistance. Methods: We first tested the activity of PCX to inhibit migration of CCA cells. We then prepared PCX/anti-miRNA nanoparticles and analyzed their miRNA delivery efficacy and anticancer activity in vitro. Finally, in vivo biodistribution assay and anticancer activity study were performed in CCA tumor-bearing mice. Results: Our results show that PCX had a broad inhibitory effect on cell migration, effectively delivered anti-miR-210, and downregulated miR-210 expression in CCA cells. Combination PCX/anti-miR-210 nanoparticles showed cytotoxic activity towards CCA cells and reduced the number of cancer stem-like cells. The nanoparticles reversed hypoxia-induced drug resistance and sensitized CCA cells to standard gemcitabine and cisplatin combination treatment. Systemic intravenous treatment with the nanoparticles in a CCA xenograft model resulted in prominent combined antitumor activity. Conclusion: Our findings support PCX-based nanoparticles as a promising delivery platform of therapeutic miRNA in combination CCA therapies.",
keywords = "Cholangiocarcinoma, Drug resistance, Hypoxia, MiRNA, Nanoparticles",
author = "Ying Xie and Yazhe Wang and Jing Li and Yu Hang and Lee Jaramillo and Wehrkamp, {Cody J.} and Phillippi, {Mary Anne} and Mohr, {Ashley M.} and Yi Chen and Talmon, {Geoffrey A} and Mott, {Justin L} and David Oupicky",
year = "2018",
month = "1",
day = "1",
doi = "10.7150/thno.26506",
language = "English (US)",
volume = "8",
pages = "4305--4320",
journal = "Theranostics",
issn = "1838-7640",
publisher = "Ivyspring International Publisher",
number = "16",

}

TY - JOUR

T1 - Cholangiocarcinoma therapy with nanoparticles that combine downregulation of MicroRNA-210 with inhibition of cancer cell invasiveness

AU - Xie, Ying

AU - Wang, Yazhe

AU - Li, Jing

AU - Hang, Yu

AU - Jaramillo, Lee

AU - Wehrkamp, Cody J.

AU - Phillippi, Mary Anne

AU - Mohr, Ashley M.

AU - Chen, Yi

AU - Talmon, Geoffrey A

AU - Mott, Justin L

AU - Oupicky, David

PY - 2018/1/1

Y1 - 2018/1/1

N2 - Cholangiocarcinoma (CCA) is the second most common primary liver malignancy with extremely poor therapeutic outcome due to high drug resistance, widespread metastasis and lack of effective treatment options. CCA progression and metastasis are regulated by multiple biological factors including multiple miRNAs and chemokine receptor CXCR4. The goal of this study was to test if nanotherapeutic blockade of CXCR4 by polymeric CXCR4 antagonist (PCX) combined with inhibition of hypoxia-inducible miR-210 cooperatively enhances therapeutic efficacy in CCA through reducing invasiveness, inducing cell killing, and reversing drug resistance. Methods: We first tested the activity of PCX to inhibit migration of CCA cells. We then prepared PCX/anti-miRNA nanoparticles and analyzed their miRNA delivery efficacy and anticancer activity in vitro. Finally, in vivo biodistribution assay and anticancer activity study were performed in CCA tumor-bearing mice. Results: Our results show that PCX had a broad inhibitory effect on cell migration, effectively delivered anti-miR-210, and downregulated miR-210 expression in CCA cells. Combination PCX/anti-miR-210 nanoparticles showed cytotoxic activity towards CCA cells and reduced the number of cancer stem-like cells. The nanoparticles reversed hypoxia-induced drug resistance and sensitized CCA cells to standard gemcitabine and cisplatin combination treatment. Systemic intravenous treatment with the nanoparticles in a CCA xenograft model resulted in prominent combined antitumor activity. Conclusion: Our findings support PCX-based nanoparticles as a promising delivery platform of therapeutic miRNA in combination CCA therapies.

AB - Cholangiocarcinoma (CCA) is the second most common primary liver malignancy with extremely poor therapeutic outcome due to high drug resistance, widespread metastasis and lack of effective treatment options. CCA progression and metastasis are regulated by multiple biological factors including multiple miRNAs and chemokine receptor CXCR4. The goal of this study was to test if nanotherapeutic blockade of CXCR4 by polymeric CXCR4 antagonist (PCX) combined with inhibition of hypoxia-inducible miR-210 cooperatively enhances therapeutic efficacy in CCA through reducing invasiveness, inducing cell killing, and reversing drug resistance. Methods: We first tested the activity of PCX to inhibit migration of CCA cells. We then prepared PCX/anti-miRNA nanoparticles and analyzed their miRNA delivery efficacy and anticancer activity in vitro. Finally, in vivo biodistribution assay and anticancer activity study were performed in CCA tumor-bearing mice. Results: Our results show that PCX had a broad inhibitory effect on cell migration, effectively delivered anti-miR-210, and downregulated miR-210 expression in CCA cells. Combination PCX/anti-miR-210 nanoparticles showed cytotoxic activity towards CCA cells and reduced the number of cancer stem-like cells. The nanoparticles reversed hypoxia-induced drug resistance and sensitized CCA cells to standard gemcitabine and cisplatin combination treatment. Systemic intravenous treatment with the nanoparticles in a CCA xenograft model resulted in prominent combined antitumor activity. Conclusion: Our findings support PCX-based nanoparticles as a promising delivery platform of therapeutic miRNA in combination CCA therapies.

KW - Cholangiocarcinoma

KW - Drug resistance

KW - Hypoxia

KW - MiRNA

KW - Nanoparticles

UR - http://www.scopus.com/inward/record.url?scp=85052621837&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85052621837&partnerID=8YFLogxK

U2 - 10.7150/thno.26506

DO - 10.7150/thno.26506

M3 - Article

C2 - 30214622

AN - SCOPUS:85052621837

VL - 8

SP - 4305

EP - 4320

JO - Theranostics

JF - Theranostics

SN - 1838-7640

IS - 16

ER -